Webster N J, Kong Y, Sharma P, Haas M, Sukumar S, Seely B L
UCSD/Whittier Diabetes Program, University of California, San Diego, La Jolla 92093, USA.
Biochem Mol Med. 1997 Dec;62(2):139-50. doi: 10.1006/bmme.1997.2648.
The Wilms tumor gene WT1 has been implicated in the early development of the kidney. Mutations in WT1 are found in a small fraction of Wilms tumor, a pediatric nephroblastoma, and Denys-Drash syndrome, characterized by genitourinary abnormalities. The WT1 gene product functions as a transcriptional repressor of growth factor-related genes. The kidney is one of the major sites of insulin action in vivo and expresses high levels of insulin receptors (IR). IR expression has been detected during early embryogenesis, suggesting that it may play a role in development. We investigated whether two WT1 splice variants lacking or including a three-amino-acid (KTS) insertion between the third and fourth zinc finger in the DNA-binding domain could repress the IR promoter in vitro. We show that the +KTS variant effectively represses promoter activity under all conditions tested but the -KTS variant was only able to repress in the presence of cotransfected C/EBP beta or a dominant-negative p53 mutation. Deletional mapping indicated that distinct regions of the IR promoter mediated the effects of the two isoforms and DNaseI footprint analysis identified potential WT1 binding sites within these regions.
威尔姆斯瘤基因WT1与肾脏的早期发育有关。WT1突变见于一小部分威尔姆斯瘤(一种儿童肾母细胞瘤)以及以泌尿生殖系统异常为特征的德尼-德拉什综合征。WT1基因产物作为生长因子相关基因的转录抑制因子发挥作用。肾脏是体内胰岛素作用的主要部位之一,表达高水平的胰岛素受体(IR)。在胚胎早期发育过程中已检测到IR表达,提示其可能在发育中发挥作用。我们研究了DNA结合域中第三和第四锌指之间缺少或包含一个三氨基酸(KTS)插入的两种WT1剪接变体是否能在体外抑制IR启动子。我们发现,在所有测试条件下,+KTS变体均能有效抑制启动子活性,但-KTS变体仅在共转染C/EBPβ或显性负性p53突变存在时才能抑制。缺失定位表明IR启动子的不同区域介导了两种异构体的作用,DNaseI足迹分析确定了这些区域内潜在的WT1结合位点。